Tumor necrosis factor activities and cancer therapy--a perspective.

Tumor necrosis factor (TNF) is a multifunctional cytokine which has excited and fascinated numerous investigators and commercial entities due to its promise as a therapeutic agent against cancer and as a target for drugs treating septic shock. TNF is a protein having cytotoxic, cytostatic, immunomodulatory as well as several other activities and is also involved in septic shock. This review covers the structure of TNF and its receptors, various in vitro activities and in vivo activities based on studies in animal model systems. The role of TNF as an anticancer therapeutic agent, based on various phase I and phase II clinical studies, has also been considered. The review concludes with several considerations for increasing the therapeutic utility of TNF in terms of targeting, toxicity and half-life.

Binding of tumor necrosis factor alpha (TNF-alpha) to high-affinity receptors on polymorphonuclear cells.

The effects of tumor necrosis factor alpha (TNF-alpha) on human polymorphonuclear (PMN) cells were investigated. We found that 125I-TNF-alpha bound specifically to high-affinity receptors on PMN cells. At 4 degrees C, the binding occurred rapidly and reached steady state after 20 min. The Scatchard plot showed a single class of high-affinity receptors with approximately 2200 receptors/cell and a dissociation constant of 2 x 10(-10) M. There was a linear relationship between TNF-alpha binding and TNF-alpha-induced PMN cell adherence. The concentration of TNF-alpha required to achieve approximately 50% of maximum binding was also approximately the concentration required to reach 50% cell adherence. Auranofin was shown to inhibit TNF-alpha-induced PMN cell adherence at a dose of 5-10 micrograms/ml. This inhibitory effect was not due to the inhibition of TNF-alpha binding to PMN cells by the drug. These observations may have clinical implications.

Analysis of alpha-factor secretion signals by fusing with acid phosphatase of yeast.

In yeast, Saccharomyces cerevisiae, the PHO5 gene encodes the repressible acid phosphatase (APase) whose activity can be easily monitored by either the staining of colonies or by colorimetric assay. Therefore, gene fusions to PHO5 provide a convenient system for structural and functional analysis of yeast genes. We have constructed fusions of the PHO5 gene with a MF alpha 1 gene of yeast to delineate the secretion signal(s) in the alpha-factor leader peptide. Gene fusion between MF alpha 1 and PHO5 codes for a hybrid protein in which the alpha-factor leader peptide of 89 amino acids (aa) directed the export of APase, a periplasmic protein, into the medium. Since the hybrid gene is transcribed from the alpha-factor promoter, expression of the APase activity from these hybrid genes showed cell type-specific regulation. Further analyses of another MF alpha 1-PHO5 fusion showed that only the first 22 aa of the 89-aa alpha-factor leader peptide contained sufficient information for the secretion of APase into the medium. This shows that, in addition to the analysis of gene regulation, PHO5 fusions can be used to study signals involved in the proper localization of proteins.

Selection of secretory protein-encoding genes by fusion with PHO5 in Saccharomyces cerevisiae.

Secretory protein-encoding genes of Saccharomyces cerevisiae have been cloned by a novel procedure that is based on the functional selection of their fusions with acid phosphatase (APase) at the DNA level. DNA fragments that functionally replace the promoter and signal sequence-encoding regions of the PHO5 gene (encoding APase) have been obtained by positive selection from a pool of cloned random DNA fragments. Five unique DNA sequences containing the promoter, and encoding signal sequences have been isolated. We have also isolated the complete gene, SSP120, encoding one of these S. cerevisiae secretory proteins, SSP120. Gene disruption studies have shown that the SSP120 gene is not essential for viability and growth. The SSP120 amino acid (aa) sequence has 13.5% identity with the middle 88-250 aa residues of the chicken glycosylation site-binding protein. However, SSP120 disruption did not affect protein glycosylation in yeast. The present study provides an alternative approach for the isolation of genes encoding secretory proteins, in contrast to classical genetic approaches that require isolation of functionally defective mutations followed by gene isolation by functional complementation. The present procedure should contribute to our understanding of protein sorting by permitting the cloning of genes encoding proteins targeted to different organelles in the secretory pathway.

Pseudogene IFN-alpha L: removal of the stop codon in the signal sequence permits expression of active human interferon.

Biologically active interferon (10(6)-10(7) units/liter) was produced in Escherichia coli from modified human alpha interferon (IFN-alpha) pseudogene L. IFN-alpha pseudogene L has a stop codon in the signal peptide coding region. The region that contains the stop codon was replaced with the corresponding region of another human IFN-alpha gene, WA, that does not have a stop codon and was previously engineered for expression by fusion to the M13mp11 lac promoter. The interferon L fusion product was induced with IPTG after infecting E. coli JM103 with the M13 bacteriophage that contained the modified human IFN-alpha pseudogene L. Hence, the IFN-alpha L mature interferon coding sequence, which is not identical to any other alpha-interferon gene, has been conserved for active interferon coding information.

Purification and properties of threonine deaminase from Saccharomyces cerevisiae.

Threonine deaminase (L-theonine hydro-lyase (deaminating), E.C. 4.2.1.16) has been purified to homogeneity from extracts of Saccharomyces cerevisiae. When purified 1200-fold, the enzyme is homogeneous by the criterion of sodium dodecyl sulfate-polyacrylamide electrophoresis. The reduced and alkylated protein has a molecular weight of approximately 50,000 daltons, one-fourth the value determined previously for the intact enzyme. The purified enzyme exhibits homotropic effects with the substrate; these effects are descresed in the presence of DL-allothreonine, a competitive inhibitor. Half-maximal velocity is achieved at 34 mM L-threonine in the absence of other effectors. L-isoleucine both stimulates at low (0.01-0.05 mM) concentrations and inhibits at high (0.1-1.0 mM) concentrations. Valine activates the enzyme in the absence of isoleucine ; in the presence of isoleucine it reverses inhibition.

Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock.

Six murine monoclonal antibodies, AT-1, 2, 3, 4, 5, and 6 were produced against human recombinant tumor necrosis factor (gamma TNF). AT-1, -2, -3, -4, and -6 were IgG1, and AT-5 was IgG2a. AT-1, -2, and -3 neutralized the activity of gamma TNF (2 X 10(3) U/ml) over a range of dilutions between 5 and 500 micrograms/ml of IgG, while AT-4, -5 and -6 failed to neutralize the activity in these concentrations. All the antibodies showed immunoprecipitating activity for gamma TNF (2 X 10(3) U/ml) over a range of dilutions between 0.5 and 500 micrograms/ml. The AT-6 was weaker than the rest. AT-1, which neutralized gamma TNF activity efficiently, and AT-4, which did not neutralize the activity, were used to protect mice against endotoxic shock. AT-1 protected mice from the lethal effects of endotoxin, while AT-4 failed to do so. AT-1, -2, and -3 also neutralized the activity of human and mouse natural TNF. AT-1, -2, and -3 neutralized the activity of gamma TNF, but not that of lymphotoxin (LT) and interferon (IFN).

Tumor necrosis factor analogs: identification of functional domains.

Truncated tumor necrosis factor analogs were produced by making in vitro deletions of the coding sequence of the human TNF gene. One of these analogs, TNF-desA7, lacked seven amino terminal residues of the mature TNF protein and the other two analogs, TNF-desC7 and TNF-desC2, had deletions of seven and two carboxy terminal amino acids, respectively. While the deletion of the first seven amino acid residues did not affect the biological activity of the protein, the deletions of carboxy terminal residues in both analogs resulted in the complete loss of biological activity. A direct correlation of the biological activity of the TNF protein and its binding to neutralizing monoclonal antibodies was observed. The carboxy terminal-deleted TNF analogs, with no biological activity, did not bind to neutralizing monoclonal antibodies while the amino terminal-deleted analog, which retained complete biological activity, did bind. These results indicate that the carboxy terminal amino acids of the TNF protein are essential for TNF biological activity and are part of an epitope recognized by neutralizing monoclonal antibodies.

Mycobacterium recombinant vaccines.

Intracellular diseases are difficult to treat and constitute a major problem for modern medicine. In this type of diseases, a TH-1 immune response favors protection, while a TH-2 response is detrimental to the host. Current vaccines are using antigens to initiate an immune response regardless of its nature and its mechanism. New vaccines are designed to combine selected antigens with potent adjuvants to stimulate the appropriate pathway of the immune system and deliver a lasting protective immunity. The Mycobacterium recombinant vaccine system for treatment of intracellular diseases utilizes antigen delivery systems in the form of non pathogenic Mycobacterium strains, genetic transfer systems in the form of cloning and expression vectors, and related technologies to provide products containing non toxic immuno-regulating Mycobacterium adjuvants, non toxic immuno-stimulating exogenous antigens specific for a variety of diseases, and non toxic amounts of cytokines that boost the TH-1 pathway. The cloning and expression Mycobacterium vectors include both pAL5000-based extra-chromosomal and D29-based integrative vectors.

Analysis of yeast ilv 1 CIS control and domain mutants.

We have identified a cis control region specific for the ilv 1 gene of Saccharomyces cerevisiae. Mutants designated ilv 1-OPc map in this control region located between arg 6 and ilv 1 and result in increased basal levels and constitutive synthesis of the ilv 1 gene products. Furthermore, ilv 1 mutants have been isolated in three different structural domains indicating that the ilv 1 gene may contain a functional intervening sequence specific for one of the two gene products.

Regulation of the ilv 1 multifunctional gene in Saccharomyces cerevisiae.

The ilv 1 gene in S. cerevisiae codes for a regulatory protein involved in depression of the ilv 2 and ilv 3 genes as well as a biosynthetic enzyme, threonine deaminase. 2. The ilv 1 gene does not autogenously regulate its catalytic product threonine deaninase. 3. Regulation of the ilv 2 and ilv 3 gene products involve different aporepressors than regulation of the ilv 1 gene product. 4. The ilv I multifunctional gene in S. cerevisiae may be a duplication and fusion of a bacterial like ilv 1 gene where ilv 1 catalytic and regulatory function have been differentially conserved.

Characterization of yeast ribosomal DNA fragments generated by EcoR1 restriction endonuclease.

The action of Escherichia coli restriction endonuclease R1 (EcoR1) on DNA isolated from Saccharomyces cerevisiae (strain MAR-33) generates three predominent homogenously sized DNA fragments (species of 1.8, 2.2 and 2.5 kilo nucleotide base pairs (KB). Many DNA species of molecular weight greater than 2 million daltons can be recognized upon incomplete EcoR1 digestion of yeast DNA. Four additional DNA species ranging from 0.3--0.9 KB can be identified as the second major class of EcoR1-yeast DNA products. Hybridization with radioactive ribosomal RNA (rRNA) and competition with nonradioactive rRNA show that of the three predominent EcoR1-yeast DNA species, the 2.5 KB species hybridizes only with the 25S rRNA while the lighter 1.8 KB species hybridizes with the 18S rRNA. The intermediate DNA species of 2.2 KB hybridizes to a small extent with the 25S rRNA and could be a result of the presence of the 2.5 KB DNA species. The mass proportions and hybridization values of these 3 DNA species account for about 60% of the total ribosomal DNA (rDNA). The 5 Eco-R1-yeast DNA species of less than 0.9 KB (4 major and 1 minor species) hybridize to varying degrees with the 2 rRNA and can be grouped in two classes. In one class there are 3 DNA species that hybridize exclusively with the 18S rRNA. In the second class there are 2 DNA species that besides hybridizing predominently with the 25S rRNA also hybridize with the 18S rRNA. The 7 EcoR1-yeast DNA species (excluding the 2.2 KB DNA species) that hybridize with the two rRNA account for nearly a 5 million dalton DNA segment, which is very close to the anticipated gene size of rRNA precursor molecule. If the 2.2 KB DNA species is a part of the rDNA that is not transcribed or 5 sRNA then the cistron encoding the rRNA in S. cerevisiae has at least 8 EcoR1 recognition sites resulting in 8 DNA fragments upon digestion with the EcoR1. Consideration is given to the relationship of the rRNA species generated by EcoR1 digestion and the chromosomes containing ribosomal cistrons.

Involvement of threonine deaminase in multivalent repression of the isoleucine-valine pathway in Saccharomyces cerevisiae.

A strain (MAR33) of Saccharomyces cerevisiae containing a threonine deaminase [L-threonine hydrolyase (deaminating) EC 4.2.1.16] with decreased feedback sensitivity has been shown to have a specific activity of acetohydroxy acid synthetase higher than that of the parent strain (MD11) when both are grown on minimal medium. When strain MAR33 is grown on minimal medium supplemented only with isoleucine, the specific activity of the synthetase is reduced to that found in the parent strain. Another strain, D106-1A, contains a nonsense mutation in the middle of the gene for threonine deaminase. When this strain is grown on minimal medium containing appropriate supplements (which include a nonrepressing concentration of isoleucine), or on minimal medium supplemented with isoleucylglycine (which acts as a limiting source of isoleucine), acetohydroxy acid synthetase remains repressed. Leucine limitation causes partial derepression. With the reversion of the nonsense mutation, either intragenically or via a suppressor for the mutation, partial derepression of the synthetase returns. When D106-1A is diploidized with either M15, a mutant lacking the synthetase, or MD9, a strain containing the enzyme, normal, partially derepressed, values for this enzyme are found. This indicates that threonine deaminase is necessary for derepression, and that it possibly acts as an inducer.

Regulation of argE-argH expression with arginine derivatives in Escherichia coli: extreme non-uniformity of repression and conditional repressive action.

In regulatory studies of the arginine biosynthetic system of Escherichia coli, alpha-N-acetyl-l-arginine (AcA) is a useful restrictive arginine source. In strain 39A-23R3 (argA(-)), at 25 mug/ml, AcA gives suboptimal growth rates and is fully derepressive for acetylornithinase (specified by argE) and approximately 50% derepressive for argininosuccinase (specified by argH). At 10 mug/ml, the growth rate decreases, whereas the extent of derepression is unchanged; at 500 mug/ml, full repression results. In strain 3670 (argB(-)argG(-)), AcA (25 mug/ml) leads to partial derepression of acetylornithinase but full repression of argininosuccinase. Thus, the repression patterns for both strains, although not identical, are nonuniform. AcA utilization is antagonized by alpha-N-acetyl-l-ornithine (AcO). In strain 3670 (blocked before and after acetylornithinase), the growth rate on AcA (25 mug/ml) is lowered by AcO (500 mug/ml); acetylornithinase is completely derepressed, whereas argininosuccinase is fully repressed. This difference in regulatory behavior represents extreme nonuniform repression. Unexpectedly, the effect of AcO is attributable to the conversion of AcO to citrulline (Cit). In strain 3670, mixtures of AcA (25 mug/ml) and Cit (300 mug/ml) permit complete derepression of acetylornithinase; there is evidence that Cit enters the cell. In contrast, in the arginine-limited chemostat, Cit represses acetylornithinase. These opposite regulatory effects of Cit appear to stem from the difference in arginine restriction. AcA enters the cell via AcO permease and is deacylated by acetylornithinase (K(m), 5.0 mM). AcA competitively inhibits AcO cleavage (K(i), 2.4 mM), but Cit is not inhibitory. The antagonism of AcA utilization by AcO or Cit is thought to be exerted at the AcO permease.

Involvement of threonine deaminase in repression of the isoleucine-valine and leucine pathways in Saccharomyces cerevisiae.

l-Threonine deaminase (l-threonine dehydratase [deaminating], EC 4.2.2.16) has been shown to be involved in the regulation of three of the enzymes of isoleucine-valine biosynthesis in yeast. Mutations affecting the affinity of the enzyme for isoleucine also affected the repression of acetohydroxyacid synthase, dihydroxyacid dehydrase, and reductoisomerase. The data indicate that isoleucine must be bound for effective repression of these enzymes to take place. In a strain with a nonsense mutation midway in liv 1, the gene for threonine deaminase, starvation for isoleucine or valine did not lead to derepression of the three enzymes; starvation for leucine did. The effect of the nonsense mutation is recessive; it is tentatively concluded, therefore, that intact threonine deaminase is required for derepression by two of the effectors for multivalent repression, but not by the third. A model is presented which proposes that a regulatory species of leu tRNA(leu) is the key intermediate for repression and that threonine deaminase is a positive element, regulating the available pool of charged leu tRNA by binding it.

Bacterial plasmid pBR322 sequences serve as upstream activating sequences in Saccharomyces cerevisiae.

The expression of acid phosphatase (APase) from PHO5 and MF alpha-PHO5 hybrid genes is regulated by inorganic phosphate and mating type locus respectively, as well as the PHO4 and MAT alpha 1 gene products respectively. When PHO5 and MF alpha-PHO5 hybrid genes were cloned in the BamHI site of the pBR322 sequence of the yeast shuttle vectors (YRp7 or YEp9T), in one orientation they were regulated normally but in the other orientation their expression was not regulated but expressed constitutively. The pBR322 sequences present upstream of the inserted genes are responsible for the constitutive expression. By replacing the PHO5 upstream activating sequences (UAS) element with pBR322 fragments, we have identified three pBR322 sequences, from nucleotides 376 to 650, 2068 to 2116 and 2136 to 2247, which were able to promote expression of APase. A comparison of these three pBR322 fragments revealed 5' ATCGCGCGAG 3' and 5' CGGTGATGNCGG 3' to be the common sequences likely to act as UASs in Saccharomyces cerevisiae. By using synthetic oligonucleotides, it was found that both sequences are required for maximum expression of APase activity.

Organization of the yeast ribosomal RNA gene cluster via cloning and restriction analysis.

The restriction endonuclease EcoR1 cleaves Saccharomyces cerevisiae DNA, which codes for ribosomal RNA (rRNA), into seven fragments, A second restriction endonuclease, HindIII, cleaves the same yeast ribosomal DNA into two fragments. These two restriction enzymes each yield DNA segments that total about 5.9 megadaltons. The "repeat unit" of the yeast genes coding for rRNA is thus about 5.9 megadaltons or about 9000 base pairs long. The two HindIII-cleaved DNA fragments as well as one of the EcoR1-cleaved DNA fragments were purified and amplified by cloning in Escherichia coli. Three of the seven EcoR1-generated DNA fragments could then be ordered by treating the two cloned HindIII DNA fragments with EcoR1. This led the assignment of the two HindIII restriction sites. The various restriction DNA fragments were hybridized directly from the gel utilizing 32P-labeled 5 S, 5.8 S, 18 S, and 25 S rRNA. Identification of the various DNA restriction segments then led to the final ordering of the DNA fragments. The gene coding for the 5 S RNA is adjacent to the gene coding for the 35 S precursor rRNA. These two groups of genes thus occur as a cluster in the following sequence: [5 S-spacer]-[spacer-18 S-5.8 S-25 S-spacer]-[spacer-5 S]. The actual map of the DNA restriction fragments is presented.

Effect of dibutyryl cyclic AMP and analogs on the rate of contractions of myocytes in culture.

2O, 6N-butyryl, 3', 5'-cyclic monophosphate (dibu cAMP) when added to fetal rat heart cells in culture inhibits myocyte contraction. This inhibition is 100, 84 and 51% complete when the dibu cAMP concentration used is 2, 0.2 and 0.02 mM, respectively. The potency of dibu cAMP derivatives in myocyte contraction inhibition follows the order, dibu cAMP greater than 6N-bu cAMP greater than 2O-bu cAMP = AMP greater than butyrate. The inhibition caused by the first three chemicals is greater than 70%.

Oncogene expression in human hepatoma cells PLC/PRF/5.

The expression of 7 cellular oncogenes in a human hepatoma cell line PLC/PRF/5 was studied using Northern blot analyses. Among the oncogenes tested, c-abl, c-fes, c-fms, c-myc, c-Ha-ras and c-sis were expressed. The oncogene c-Ki-ras was not expressed. The length of the mRNAs expressed was almost consistent with published data. Compared to the oncogene expression in Daudi lymphoma cells, the same kind of oncogenes were expressed in PLC/PRF/5 cells, but the intensity of the signal in each oncogene expression was stronger in Daudi cells than in PLC/PRF/5 cells. Considering the cellular localization and the function of each oncogene, the oncogene survey in hepatoma cells broadens the knowledge of hepatocarcinogenesis and the character of human hepatoma cells.